ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Chronic myelogenous leukemia (CML) patients treated with imatinib, a BCR-Abl inhibitor, can undergo relapse due to the acquisition of a secondary mutation within the Abl coding sequence [6], [7] that renders imatinib ineffective.